What is Scitara?
Scitara operates as a global leader in lab-specific iPaaS solutions, providing a cloud-based architecture designed to unify scientific workflows. The company's flagship offering, the DLX platform, facilitates the integration of laboratory instruments, automates data movement, and monitors digital transactions in real-time. By catering to the rigorous requirements of bioprocessing, quality control, and R&D labs, Scitara addresses the critical need for data integrity and operational efficiency in process-based industries. Their technology stack is engineered to eliminate data silos, allowing organizations to accelerate scientific discovery while maintaining strict adherence to regulatory compliance standards.
How much funding has Scitara raised?
Scitara has raised a total of $25M across 3 funding rounds:
Series A
$5M
Series B
$15M
Debt
$5M
Series A (2021): $5M with participation from Northpond Ventures LLC and Flybridge Capital Partners
Series B (2022): $15M led by Northpond Ventures and Flybridge Capital Partners
Debt (2026): $5M, investors not publicly disclosed
Key Investors in Scitara
Flybridge Capital Partners
Flybridge is an early-stage venture capital fund with over 20 years of investing experience and more than $1B under management, based in New York and Boston. The firm focuses on providing support to ambitious founders creating innovative companies centered around Artificial Intelligence.
Northpond Ventures
Northpond Ventures is a prominent investment firm specializing in science, technology, and healthcare, often focusing on companies that drive innovation in life sciences and digital health.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Scitara?
With the recent influx of capital, Scitara is well-positioned to expand its footprint in the enterprise software market, specifically targeting the intersection of AI-driven analytics and laboratory automation. The strategic focus will likely shift toward enhancing the scalability of the DLX platform to support larger, global biopharmaceutical deployments. By prioritizing the development of advanced data infrastructure, Scitara aims to solidify its market position as the primary middleware for the modern, connected laboratory. Future initiatives will likely involve deepening integration capabilities with emerging cloud-native scientific tools, thereby reinforcing the company's commitment to optimizing production efficiency and data-centric decision-making for its diverse client base.
See full Scitara company page
